Lilly Management Reorg Brings In Shaw To Oversee Bio-Medicines
Shaw is the former US President of rival Novartis and a rising figure in big pharma. She will take over the role previously held by Ricks, who became CEO Jan. 1. Conterno will assume President USA role.
You may also be interested in...
After heading up Lilly Bio-Medicines for two-and-a-half years, Shaw will take over Gilead’s gene therapy subsidiary. At Lilly, she oversaw the approvals of Olumiant and Emgality and helped grow Taltz.
US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.
One woman CEO is an improvement, but at this rate gender equality won't arrive before immuno-oncology goes generic.